Abstract
Omalizumab is approved for the treatment of severe allergic asthma, but not all patients indicated for this treatment respond well.1,2 Currently, patients are considered as nonresponders if no clinical benefits are established within 16 weeks since the onset of treatment.3 Because airway inflammation is a cardinal feature of asthma,4 we reasoned that early changes in its level may determine the subsequent course of the disease. We recruited for this real-life pilot study biologic therapy–naive patients with asthma eligible for omalizumab by the stringent criteria of the National Health Insurance Fund and followed them up for a period of 18 weeks: 2 weeks run-in and 16 weeks of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
